Related Experiment Videos

Strategies and options for minimizing resistance emergence in pulmonary infections

S G Amyes1

  • 1Department of Medical Microbiology, The Medical School, University of Edinburgh, Scotland.

Chest
|March 27, 1998
PubMed

Insights

Early-onset gram-negative infections respond to antibiotics like ciprofloxacin. However, late-onset pathogens show cephalosporin resistance, necessitating fluoroquinolones and carbapenems for effective treatment.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Hospital-acquired infections pose significant challenges.
  • Antimicrobial resistance is a growing concern in clinical settings.
  • Understanding pathogen susceptibility is crucial for effective treatment.

Purpose of the Study:

  • To evaluate antibiotic efficacy against early- and late-onset hospital-acquired pulmonary pathogens.
  • To identify emerging resistance patterns in common hospital-acquired infections.
  • To guide optimal antibiotic selection based on resistance data.

Main Methods:

  • Retrospective analysis of clinical data.
  • Review of antibiotic susceptibility testing results.
  • Assessment of treatment outcomes for different pathogen types.

Main Results:

  • Early-onset gram-negative infections showed susceptibility to ciprofloxacin and co-amoxiclav.
  • Penicillin-resistant Streptococcus pneumoniae was treatable with macrolides, fluoroquinolones, and glycopeptides.
  • Late-onset pathogens exhibited resistance to cephalosporins, favoring fluoroquinolones and carbapenems.

Conclusions:

  • Ciprofloxacin and co-amoxiclav are viable options for early-onset gram-negative pulmonary infections.
  • Fluoroquinolones and carbapenems are essential for treating late-onset infections due to cephalosporin resistance.
  • Treatment strategies must adapt to evolving antimicrobial resistance patterns.

Related Concept Videos